Abstract: Methods and systems including a set of interacting nucleic acid structures for use in detecting and/or identifying a target comprising: a nucleic acid sequence capable of being conjugated to a moiety directed to the target; and a nucleic acid nanostructure comprising a segment sequence complementary to a portion of the nucleic acid sequence capable of being conjugated to a moiety directed to the target. The moiety directed to the target may be an antibody, and the nucleic acid nanostructure may be a tetrahedron.

Abstract: The present invention relates to a biomarker composition for diagnosing and predicting prognosis of prostate cancer, and that the detection rate and expression level of gene combination composed with AR (Androgen receptor), AR-V7 (Androgen receptor variant 7), EpCAM (Epithelial cell adhesion molecule) in blood tumor cells (CTC) isolated from patients, Epithelial cell adhesion molecule), KRT-19 (Cytokeratin 19), PSA (Prostate specific antigen), and PSMA (Prostate specific membrane antigen) in circulating tumor cells (CTCs) isolated from patients is related to the level of malignancy in prostate cancer is confirmed and thus the gene combination provides as a biomarker for prostate cancer diagnosis and a biomarker for prognosis prediction of prostate cancer.

Abstract: A Cyclo (his-pro) (CHP) is useful for preventing, ameliorating, or treating fibrosis. A pharmaceutical composition containing CHP may be used for preventing or treating fibrosis. A health functional food composition containing CHP may be used for preventing or ameliorating fibrosis. An antifibrotic composition, a method of preventing, ameliorating, or treating fibrosis by using CHP, and/or a use of CHP in the manufacture of the pharmaceutical composition for preventing or treating fibrosis are disclosed.

Abstract: Provided is a medical implant including: an implant base having a surface made of a silicon material; a linker having one end attached onto the surface of the implant base; and a cytokine bound to another end of the linker. By inducing the secretion of anti-inflammatory cytokines, a capsular contracture, which is one of the complications that may occur after transplantation of the patient's breast implant, may occur less.

Abstract: A cyclo(His-Pro)(CHP) is useful for preventing, alleviating or treating peritoneal fibrosis. A pharmaceutical composition for preventing or treating peritoneal fibrosis, a dietary supplement composition for preventing or alleviating peritoneal fibrosis, and a peritoneal dialysis solution, which all contain CHP is disclosed. Also disclosed are a method for preventing or treating peritoneal fibrosis by using CHP, a peritoneal dialysis method using CHP, a use of CHP during the preparation of a pharmaceutical composition for preventing or treating peritoneal fibrosis, and/or a use of CHP in the preparation of a peritoneal dialysis solution.

Abstract: A wound dressing patch includes a backing film; an absorbent foam pad coupled to the a portion of one surface of the backing film; an adhesive sheet provided on a remaining portion of the one surface of the backing film; and a lining material provided along a peripheral edge portion of the adhesive sheet and configured to impart a predetermined stiffness to the backing film. The lining material is spaced apart from the absorbent foam pad to surround the absorbent foam pad in a form of a substantially closed curve along the peripheral edge portion of the adhesive sheet, and a distance between the lining material and an end of the adhesive sheet is shorter than a distance between the lining material and an edge of the absorbent foam pad.

Abstract: An auxiliary device for use in a trocar instrument, including a trocar needle having a fastening groove formed on an outer circumferential surface thereof. The auxiliary device includes: a body into which at least a portion of the trocar needle is inserted; and a hook connected to the body and configured to be inserted into the fastening groove of the trocar needle. The hook includes a fixing portion fixed to the body and a coupling portion extending from one end of the fixing portion and configured to be inserted into the fastening groove when the trocar needle is disposed inside the body. A gap is formed between the fixing portion and the coupling portion.

Abstract: The present disclosure discloses a biomarker capable of predicting the therapeutic response to anticancer agents and prognosis of triple-negative breast cancer patients, and the use thereof. A biomarker according to the present disclosure allows the provision of optimized personal therapeutic methods through correct personalized treatment, contributing to the quality and prolongation of life of patients.

Abstract: A mitral valve prosthesis to be implanted in a heart, comprises an asymmetrical ring, the asymmetrical ring is dimensioned to mimic a native mitral annulus of a patient; an anterior flexible leaflet and a posterior flexible leaflet, said leaflets suspended from the asymmetrical ring and configured to substantially coapt with each other; and at least four sets of cords, each set of cords attached to the anterior or posterior leaflet on a first end and attached into a cap on a second end, the cap is configured to be attached onto papillary muscles of the heart on another end of the cap.

Abstract: The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERR?) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.

Abstract: Provided is a pulmonary edema monitoring apparatus, which is always attached to the body and is capable of continuously monitoring whether a pulmonary edema occurs, for a patient with advanced disease or a shock patient. This pulmonary edema monitoring apparatus includes: an ultrasound frequency module which is attached to the chest of a patient, generates an ultrasound, and receives a reflection wave reflected from the inside of a human body; and a control module which measures the intensity (this is referred to as “ultrasound radio frequency data”) of the reflection wave, determines whether a pulmonary edema occurs on the basis of an increasing rate of the ultrasound radio frequency data according to a degree of multiple reflection, and provides an alarm.

Abstract: Disclosed are a method for preparing induced pluripotent stem cells from endocardium-derived adult stem cells isolated from peripheral blood and a method for differentiating induced pluripotent stem cells into cardiovascular cells. The endocardium-derived adult stem cells are primary culture cells for preparing induced pluripotent stem cells, can be readily isolated and cultured only with a small amount of peripheral blood, have a high proliferation property so as to be storable without generic variation, and can rapidly ensure a cell number so as to be usable in cell therapy. The endocardium-derived adult stem cells have sternness, thereby having high preparation efficiency, and are derived from the endocardium so as to have the epigenetic memory of cardiovascular cells, thereby having an advantage of being able to be differentiated, after preparing induced pluripotent stem cells, into cardiovascular cells such as endothelial cells, smooth muscle cells and cardiomyocytes with a high efficiency.

Abstract: The present invention relates to a novel Usnic acid derivative exhibiting an inhibitory effect on TSLP secretion or pharmaceutically acceptable salts thereof, and a use thereof.

Abstract: The is provided a compound of formula I or II or physiologically acceptable salts or solvates, or oxidised derivatives thereof: where R1 to R3, R13 and R14 are as defined herein. Also disclosed herein are methods of dyeing hair or (temporarily) tattooing the skin using the compounds of formula I or II (or physiologically acceptable salts or solvates, or oxidised derivatives thereof) in a suitable composition.

Abstract: Provided are a method of preventing and/or treating an eye disease, using a Cas9 protein and a guide RNA targeting VEGF-A, and a ribonucleoprotein including a Cas9 protein and a guide RNA targeting VEGF-A.

Abstract: The present invention relates to a polypeptide derived from CAP1 and a pharmaceutical composition comprising the same as an effective ingredient and, more particularly, to a peptide including the amino acid sequence of SEQ ID NO: 1, any 0 to 20 amino acid residues added to the N terminus thereof, and any 0 to 75 amino acid residues added to the C terminus thereof, and a pharmaceutical composition comprising the peptide as an effective ingredient for the prevention and alleviation of inflammatory diseases, the inhibition of cancer and cancer metastasis, the prevention and alleviation of diabetes, the prevention and alleviation of arteriosclerosis or cardiovascular diseases, and the prevention and alleviation of heart failure.